title: Management of the insulin resistance syndrome.
abstract: The insulin resistance syndrome (IRS) is a common disorder, which has important clinical implications. It is a cluster of cardiovascular risk factors that include obesity, hypertension, dyslipidemia, glucose intolerance, and type 2 diabetes mellitus. Lifestyle modifications and insulin sensitizers are among the several therapeutic strategies available for the treatment of the IRS. Optimal treatment will not only improve glycemic control, but may also significantly lower cardiovascular disease.
authors.affiliation: Tulane University Health Sciences Center, Department of Medicine, Section of Endocrinology SL53, 1430 Tulane Avenue, New Orleans, LA 70112-2699, USA.
authors.forename: C
authors.initials: C
authors.lastname: Desouza
authors.forename: L
authors.initials: L
authors.lastname: Gilling
authors.forename: V
authors.initials: V
authors.lastname: Fonseca
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D018149:Glucose Intolerance / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D009765:Obesity; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents